Escient Pharmaceuticals is a biotech startup that operates in the healthcare sector, specifically in the development of innovative therapeutic solutions. The company uses advanced medicinal chemistry and biological tools to create targeted small molecule therapeutics, which are essentially small molecules that can modulate the function of a specific target, such as a protein, in the body. These therapeutics have the potential to become unique treatment options for a wide range of diseases.

Escient's primary focus is on a new class of cell surface receptors called Mas-related G protein-coupled receptors (MRGPRs). These receptors are involved in various physiological and pathological processes, and by targeting them, Escient aims to develop treatments for diseases that currently have insufficient or nonexistent solutions.

The company's lead programs are EP262 and EP547, which are being evaluated for use in chronic urticaria (a type of skin rash) and other mast cell mediated disorders, and cholestatic pruritus (itching caused by bile flow obstruction), respectively.

Escient's business model revolves around the research, development, and eventual commercialization of these novel therapeutics. The company's revenue is expected to come from the sales of these drugs once they have been approved for use in the market.

The company prides itself on its culture of innovation, collaboration, transparency, mutual respect, and integrity, and sees itself as a pioneer in its field.

Keywords: Biotech, Healthcare, Therapeutic Solutions, Medicinal Chemistry, Biological Tools, Small Molecule Therapeutics, Mas-related G Protein-coupled Receptors, Chronic Urticaria, Cholestatic Pruritus, Drug Development.